GlassScriptPhysician profile
Rosa Maria Phillips
NPI 1467063610
$3,265.07
in general payments reported to CMS, 2019-2025
32 companies · $603 in 2025
The $603 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.71 · 2022: $204 · 2023: $1,523 · 2024: $908 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $371.73 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $279.11 | 2023-2025 | |
| Lilly USA, LLC | $277.72 | 2022-2025 | Mounjaro, Jardiance, Baqsimi |
| Abbott Laboratories | $269.40 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $211.46 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Amgen INC. | $210.78 | 2023-2025 | Prolia, Evenity, Tepezza |
| Xeris Pharmaceuticals, INC. | $206.42 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $204.45 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $198.10 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $113.31 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $111.77 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $73.02 | 2023-2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $64.46 | 2024 | Tymlos |
| Insulet Corporation | $59.13 | 2023-2024 | Omnipod |
| Abbvie INC. | $58.42 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $58.12 | 2024-2025 | Qsymia |
| Novartis Pharmaceuticals Corporation | $56.61 | 2023-2024 | |
| Cequr Corporation | $56.48 | 2023-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.23 | 2023-2025 | Jardiance |
| Sequel Med Tech, LLC | $44.73 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $42.59 | 2024-2025 | Yorvipath |
| Mannkind Corporation | $37.30 | 2023-2025 | Afrezza |
| Regeneron Healthcare Solutions, INC. | $36.14 | 2023 | Evkeeza |
| Amneal Pharmaceuticals LLC | $33.30 | 2023 | Unithroid |
| Astellas Pharma US INC | $24.58 | 2025 | Veozah |
| Verity Pharmaceuticals INC. | $19.33 | 2025 | Tlando |
| Ionis Pharmaceuticals, INC. | $17.64 | 2025 | Tryngolza |
| Acella Pharmaceuticals, LLC | $16.72 | 2024 | NP Thyroid 60 |
| Alvogen INC | $15.10 | 2023 | Teriparatide |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2023 | Cycloset |
| Antares Pharma, INC. | $14.71 | 2025 | Xyosted |
| Nevro Corp. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.